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Aspirin and Newer Orally Active Antiplatelet Agents in the Treatment
of the Post-Myocardial Infarction Patient
CARL J. PEPINE, MD, FACC
Gainesville, Florida
The thienopyridine derivatives, ticlopidine and clopidogrel,
provide alternatives to aspirin for use in the prevention of
recurrent ischemic events in the post–myocardial infarction pa-
tient. These drugs act through a different mechanism than aspirin
and, as a result, have potentially different profiles of safety and
efficacy. The following discusses the clinical data collected sup-
porting the use of these drugs for secondary prevention and the
unanswered questions that remain regarding their use in sub-
populations of individuals at risk. Based on the available data, it
may be concluded that aspirin should remain the drug of choice
for the prevention of recurrent ischemic events in the majority of
patients who have suffered a recent myocardial infarction.
(J Am Coll Cardiol 1998;32:1126–8)
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Antiplatelet therapy is recognized to reduce the risk of subse-
quent ischemic events in individuals who have experienced a
myocardial infarction (1). The Antiplatelet Trialists’ have
estimated that the risk of secondary myocardial infarction,
stroke, or vascular mortality (vascular ischemic events) is
reduced by approximately 25% in individuals with a suspected
acute myocardial infarction or a past history of myocardial
infarction. These findings are based almost exclusively on trials
that have evaluated the efficacy of aspirin (1), and the question
has arisen as to whether the risk of secondary ischemic events
can be further reduced with newer orally active alternative
antiplatelet agents.
Ticlopidine and clopidogrel are thienopyridine derivatives
that inhibit platelet aggregation through a fundamentally
different mechanism than aspirin (2). While aspirin inhibits
platelet aggregation by blocking the synthesis of thromboxane
A2, a substance that causes both vasoconstriction and ampli-
fication of the platelet activation process, the thienopyridines
inhibit platelet aggregation by blocking the binding of ADP,
another substance that amplifies platelet activation. The ques-
tion has therefore arisen as to whether this alternative ap-
proach to platelet inhibition might yield improved therapeutic
benefit.
Information on the utility of ticlopidine in preventing
recurrent coronary ischemic events is limited to the Studio
della Ticlopidina nell’ Angina Instabile (STAI) trial (3). This
randomized, but unblinded, trial compared the incidence of
atherothrombotic events in patients with unstable angina who
received only customary treatment (beta-blockers, calcium
antagonists, and nitrates) against those who received both
250 mg of ticlopidine twice daily plus customary treatment.
Although this trial demonstrated a significant decrease in
nonfatal myocardial infarctions and vascular death in the
ticlopidine-treated group, it is unclear whether the observed
results represent an improvement over aspirin. Furthermore,
the safety profile for ticlopidine is less favorable than that for
aspirin. The use of ticlopidine has been associated with an
increased incidence of very serious hematologic problems such
as neutropenia (4) and thrombotic thrombocytopenic purpura
(5). Thus, ticlopidine use has been reserved for those patients
who are unable to tolerate aspirin.
Clopidogrel, though differing from ticlopidine only by the
addition of an acetate ester, has not demonstrated hematotox-
icity similar to that of ticlopidine in the 11,0001 patients in
which its safety has been tested (6), suggesting increased utility
in patients. However, the existing clinical data on clopidogrel
(7) have generated considerable debate as to whether clopi-
dogrel provides a superior therapeutic benefit to that of aspirin
in the post–myocardial infarction patients. At the heart of this
debate is the CAPRIE trial (Clopidogrel versus Aspirin in
Patients at Risk of Ischemic Events), the largest trial yet that
has directly compared the efficacy of an alternative antiplatelet
agent with that of aspirin in reducing atherothrombotic events
(7). The CAPRIE trial enrolled a total of over 19,000 patients,
the distribution of which was evenly divided between three
prospectively defined populations of patients: those who had
experienced 1) a recent myocardial infarction, 2) a recent
stroke, or 3) significant peripheral arterial disease. Subjects in
the trial were randomly assigned to take either 325 mg of plain
aspirin or 75 mg of clopidogrel once daily, and after up to 3
years (1.9 years on average) of treatment, the combined
incidence of myocardial infarction, stroke, and vascular death
in the aspirin- and clopidogrel-treated groups were compared.
This trial showed an overall reduction in the rate of subsequent
atherothrombotic events in favor of clopidogrel. Clopidogrel-
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treated patients experienced either a myocardial infarction,
stroke, or vascular death at a rate of 5.32% per year, while
aspirin-treated patients had an event rate of 5.83% per year; a
relative risk reduction of 8.7% in favor of clopidogrel (p 5
0.043).
Although the overall result of the trial favored clopi-
dogrel, an analysis conducted to verify the homogeneity of
the response among the three populations of patients
indicated that the benefit was not evenly distributed among
these groups. Significant heterogeneity (p 5 0.042) across
subgroups was observed, with the majority of clopidogrel’s
benefit occurring in patients that entered the trial with
peripheral arterial disease. Patients who entered the trial
because of a recent myocardial infarction showed no reduc-
tion in the risk of subsequent ischemic events when the
clopidogrel- and aspirin-treated groups were compared. In
fact, a nonsignificant relative risk increase of 23.7% (95%
CI 5 222.1 to 12.0) was seen in the clopidogrel-treated
patients. The basis for this difference is currently unknown,
but the possibility exists that a selection bias may have been
introduced by indication. That is, the selection of patients
with a particular manifestation of atherothrombotic disease
as defined in the study protocol may have introduced
patients with other cofounders that ultimately affected the
outcome. Although the meaning of the heterogeneity be-
tween the groups continues to be the subject of considerable
debate, the data suggest that in patients with a recent
myocardial infarction, clopidogrel may be no more effective
than aspirin. Unfortunately, the CAPRIE trial is the only
trial thus far to evaluate the effectiveness of clopidogrel in
secondary prevention. Until this issue is further explored,
questions will remain regarding the relative benefit of
clopidogrel in the coronary artery disease patient.
If the issue of heterogeneity is ignored, and it is assumed
that the overall result reflects a true benefit of clopidogrel over
aspirin in all of the subpopulations of patients that were
studied in CAPRIE, the clinical significance of this result
deserves comment. Based on prior estimates of the efficacy of
aspirin in preventing recurrent thromboembolic events (1) and
the results obtained in CAPRIE, it has been estimated that in
a patient population similar to that in CAPRIE, aspirin will
prevent 19 major events per year for every 1,000 high-risk
patients that are treated, while clopidogrel will prevent 24
major events in the same group (7). Thus, it would require
switching 200 patients from aspirin to clopidogrel to see even
one less event per year. If the 95% confidence interval for the
overall result is used, the number of patients required to be
switched might actually fall between 120 and 5,000, depending
on the play of chance. This additional benefit is relatively
small, and is unlikely to offset the much higher cost of
clopidogrel over aspirin.
Given the relatively small benefit that the overall result
of CAPRIE suggests, and the uncertainty surrounding the
potential for clopidogrel to outperform aspirin in patients
who have experienced a recent myocardial infarction, the
decision to shift a patient who would otherwise receive
aspirin must rely on other factors. The CAPRIE trial
demonstrated no substantive safety benefit of either aspirin
or clopidogrel. Both drugs were tolerated to essentially the
same extent. The rate of withdrawal from treatment because
of adverse events was the same in both groups (11.4%), and
the types of adverse events were similar for both drugs (e.g.,
upper gastrointestinal discomfort and general bleeding dis-
orders were the most common adverse events for both
drugs). Although upper gastrointestinal effects were some-
what more common in the aspirin-treated patients, the dose
of aspirin used in this trial was in excess of that recognized
to be effective in secondary prevention. Thus, it is likely that
the incidence of these events would have been more com-
parable if a lower dose of aspirin or an enteric-coated
formulation had been used.
In the absence of a tangible advantage with respect to
efficacy or safety, there appears to be no justification at this
time for a wholesale shift in treatment strategy for the symp-
tomatic coronary disease patient. Clopidogrel may, however,
prove to be a valuable therapeutic agent in the small number of
patients with a prior myocardial infarction or unstable angina
who are unable to tolerate aspirin either because of anaphy-
lactic reactions, or abnormally severe gastrointestinal irrita-
tion. Clopidogrel is also expected to be a valuable replacement
for ticlopidine when used in combination with aspirin in the
acute treatment of interventional patients (such as those have
stent implantation), but this is unproven. The CLASSICS
(CLopidogrel ASpirin Stent International Cooperative Study)
trial, a comparison of aspirin plus clopidogrel versus aspirin
plus ticlopidine in the prevention of stent thrombosis, is
currently in the planning stages. It is expected to provide
information about the utility of combining clopidogrel with
aspirin in the patient at risk of recurrent coronary thrombotic
events.
Another question is whether clopidogrel used in combina-
tion with aspirin may provide a greater benefit than that
achieved with either agent alone. The CURE (Clopidogrel in
Unstable angina to prevent Recurrent ischemic Events) trial, a
comparison of nonfatal myocardial infarction and vascular
death in unstable angina patients receiving clopidogrel (75 mg)
plus aspirin versus aspirin alone, is also in the planning stages.
It should provide information about the benefits of combining
aspirin with clopidogrel in patients at risk of recurrent coro-
nary ischemic events. However, based on the currently avail-
able information, aspirin remains the drug of choice for the
majority of post–myocardial infarction patients for whom
long-term antiplatelet therapy is recommended. There is no
convincing evidence that clopidogrel provides any benefit with
respect to efficacy, safety, cost, or availability that would justify
its supplanting the use of aspirin in the treatment of the
post–myocardial infarction patient.
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